SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-23-001391 from Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc.
Date: Jan. 13, 2023 · CIK: 0001716947 · Accession: 0001493152-23-001391

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-269157

Date
Jan. 13, 2023
Author
Lynn Kirkpatrick
Form
CORRESP
Company
Ensysce Biosciences, Inc.

Letter

Ensysce Biosciences, Inc.

Ivanhoe Avenue, Suite 201

La Jolla, California 92037

January 13, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, NE

Washington, D.C. 20549

Attention: Tyler Howes, Esq.

Re: Ensysce Biosciences, Inc.

Registration Statement on Form S-3

SEC File No. 333-269157

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-269157) (the “Registration Statement”) be accelerated to 4:00 PM, Eastern Time, on Tuesday, January 17, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel by calling Gregory Rubis, Esq. at (609) 951-4105.

Please direct any questions or comments concerning this request to Mr. Rubis of Troutman Pepper Hamilton Sanders LLP.

ENSYSCE BIOSCIENCES, INC.

By: /s/ Lynn Kirkpatrick

Name: Lynn Kirkpatrick

Title:

CEO

Cc: Eric D. Kline, Troutman Pepper Hamilton Sanders LLP

Gregory Rubis, Troutman Pepper Hamilton Sanders LLP

Show Raw Text
CORRESP
1
filename1.htm

Ensysce
Biosciences, Inc.

7946
Ivanhoe Avenue, Suite 201

La
Jolla, California 92037

January
13, 2023

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, NE

Washington,
D.C. 20549

Attention:
Tyler Howes, Esq.

    Re:
    Ensysce
    Biosciences, Inc.

    Registration
    Statement on Form S-3

    SEC
    File No. 333-269157

Ladies
and Gentlemen:

Pursuant
to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc.
(the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3
(File No. 333-269157) (the “Registration Statement”) be accelerated to 4:00 PM, Eastern Time, on Tuesday, January
17, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders
LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our
counsel by calling Gregory Rubis, Esq. at (609) 951-4105.

Please
direct any questions or comments concerning this request to Mr. Rubis of Troutman Pepper Hamilton Sanders LLP.

    ENSYSCE
    BIOSCIENCES, INC.

    By:
    /s/
    Lynn Kirkpatrick

    Name:
    Lynn
    Kirkpatrick

    Title:

    CEO

    Cc:
    Eric
    D. Kline, Troutman Pepper Hamilton Sanders LLP

    Gregory
    Rubis, Troutman Pepper Hamilton Sanders LLP